146 studies found for:    rsv
Show Display Options
Rank Status Study
1 Completed Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01;   Drug: Normal Saline
2 Completed Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)
Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: ALN-RSV01;   Drug: normal saline
3 Recruiting RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: PanAd3-RSV given intra-nasally;   Biological: MVA-RSV given by intra-muscular injection;   Biological: PanAd3-RSV given by intra-muscular injection
4 Not yet recruiting Management of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients in the Neonatal Intensive Care Unit (NICU) and Control of Epidemics: TurkNICU-RSV Trial
Conditions: Respiratory Syncytial Virus Infections;   Infections, Epidemics
Intervention:
5 Completed Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
Condition: RSV Bronchiolitis
Intervention: Drug: Azithromycin
6 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV cps2 Vaccine;   Biological: Placebo Vaccine
7 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV cps2 Vaccine;   Biological: Placebo Vaccine
8 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine;   Biological: Placebo (1x Leibovitz L-15 medium)
9 Withdrawn Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome
Condition: Insulin Resistance
Interventions: Drug: Placebo;   Drug: Resveratrol
10 Recruiting Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV MEDI ΔM2-2 vaccine;   Biological: Placebo vaccine
11 Not yet recruiting Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 Vaccine;   Biological: Placebo Vaccine
12 Completed
Has Results
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: motavizumab (MEDI-524);   Biological: palivizumab
13 Unknown  Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance
Condition: Impaired Glucose Tolerance
Interventions: Dietary Supplement: resveratrol;   Drug: Placebo
14 Completed Intra-nasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)
Condition: RSV Infection
Interventions: Drug: MEDI-557;   Other: Placebo
15 Completed Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study
Conditions: RSV Infection;   Bronchiolitis
Intervention: Other: Collection of exhaled breath
16 Completed RSV-F Vaccine Dose Ranging Study in Young Women
Condition: Respiratory Syncytial Virus (RSV)
Interventions: Biological: Low dose RSV-F Vaccine with Adjuvant;   Biological: Low dose RSV-F Vaccine without Adjuvant;   Biological: High dose RSV-F Vaccine with Adjuvant;   Biological: High dose RSV-F Vaccine without Adjuvant;   Biological: Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing];   Biological: Placebo
17 Completed Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
Condition: Respiratory Syncytial Virus Infections
Intervention: Drug: ALN-RSV01
18 Completed RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
Condition: Respiratory Syncytial Virus (RSV)
Interventions: Biological: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28);   Biological: Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28);   Biological: High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28);   Biological: High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28);   Biological: Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
19 Completed Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV-F Particle Vaccine;   Biological: Placebo
20 Active, not recruiting Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines
Condition: Infections, Respiratory Syncytial Virus
Interventions: Biological: RSV vaccine GSK3003892A (formulation 1);   Biological: RSV vaccine GSK3003893A (formulation 2);   Biological: RSV vaccine GSK3003895A (formulation 3);   Biological: RSV vaccine GSK3003896A (formulation 4);   Biological: RSV vaccine GSK3003898A (formulation 5);   Biological: RSV vaccine GSK3003899A (formulation 6);   Drug: Placebo comparator

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years